Tony Mok

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi request reprint A small step towards personalized medicine for non-small cell lung cancer
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    Discov Med 8:227-31. 2009
  2. doi request reprint Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    J Clin Oncol 31:1081-8. 2013
  3. doi request reprint Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation
    Tony S K Mok
    State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China
    Drugs 72:3-10. 2012
  4. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
  5. doi request reprint Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial
    Tony S K Mok
    State Key Laboratory of Southern China, Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital Central, Hong Kong, China
    Asia Pac J Clin Oncol 7:4-12. 2011
  6. doi request reprint Personalized medicine for non-small-cell lung cancer
    Tony S Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
    Expert Rev Anticancer Ther 10:1601-11. 2010
  7. doi request reprint Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
  8. doi request reprint Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm
    Tony S K Mok
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 115:5143-54. 2009
  9. ncbi request reprint Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer
    Tony S K Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, China
    J Thorac Oncol 2:838-44. 2007
  10. ncbi request reprint Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study
    Tony S K Mok
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Oncology 71:292-6. 2006

Collaborators

Detail Information

Publications21

  1. ncbi request reprint A small step towards personalized medicine for non-small cell lung cancer
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    Discov Med 8:227-31. 2009
    ..It has become clear that personalized medicine for NSCLC is feasible. This small step towards personalized medicine represents a paradigm shift in the management of NSCLC...
  2. doi request reprint Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    J Clin Oncol 31:1081-8. 2013
    ....
  3. doi request reprint Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation
    Tony S K Mok
    State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China
    Drugs 72:3-10. 2012
    ..Earlier trials were limited by little information on the EGFR mutational status of the enrolled patients, and an ongoing phase III trial with translational biomarker analysis will provide more comprehensive data on the combination...
  4. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
    ..East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population...
  5. doi request reprint Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial
    Tony S K Mok
    State Key Laboratory of Southern China, Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital Central, Hong Kong, China
    Asia Pac J Clin Oncol 7:4-12. 2011
    ..We report the results of a preplanned analysis of Asian patients enrolled in AVAiL...
  6. doi request reprint Personalized medicine for non-small-cell lung cancer
    Tony S Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
    Expert Rev Anticancer Ther 10:1601-11. 2010
    ..In this article, we summarize the current nonpersonalized therapies and examine the available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, or metastatic disease...
  7. doi request reprint Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
    ..Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer...
  8. doi request reprint Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm
    Tony S K Mok
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 115:5143-54. 2009
    ..This could potentially establish a new standard on the clinical utility of molecular targeted agents as maintenance therapy for patients with advanced-stage NSCLC...
  9. ncbi request reprint Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer
    Tony S K Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, China
    J Thorac Oncol 2:838-44. 2007
    ..This study was designed to evaluate the efficacy and tolerability of sequential administration of irinotecan and cisplatin and then docetaxel in patients with advanced non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study
    Tony S K Mok
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Oncology 71:292-6. 2006
    ..In this study, the cytotoxic effects of patupilone (epothilone B; EPO906) were assessed in a panel of hepatocellular carcinoma (HCC) cell lines, and were compared with doxorubicin and the microtubule-stabilizing taxanes...
  11. ncbi request reprint A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
    T S K Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Institute of Chinese Medicine, Hong Kong Cancer Institute, Chinese University of Hong Kong, Hong Kong Special Administrative Region HKSAR, China
    Ann Oncol 18:768-74. 2007
    ..This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy...
  12. doi request reprint Personalized medicine in lung cancer: what we need to know
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China
    Nat Rev Clin Oncol 8:661-8. 2011
    ..Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance...
  13. ncbi request reprint A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
    Brigette Ma
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, Hong Kong Cancer Institute, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Ngan Shing Street, Shatin, New Territories, Hong Kong
    Invest New Drugs 26:169-73. 2008
    ..We tested the hypothesis that 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) may enhance response to re-treatment with gemcitabine by enhancing intracellular uptake of gemcitabine in a phase II study...
  14. doi request reprint Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer
    Tony Mok
    Department of Oncology, Prince of Wales Hospital, Hong Kong, China
    J Thorac Oncol 5:1609-15. 2010
    ..We report safety and efficacy data from a subpopulation of East/South-East (E/SE) Asian patients enrolled in a global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment study)...
  15. ncbi request reprint Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group
    Wing M Ho
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong
    Med Oncol 22:303-12. 2005
    ..In a subgroup of patients with initial inoperable liver metastases, this regimen was able to down-stage the disease to an operable stage...
  16. ncbi request reprint A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy
    Brigette Ma
    Department of Clinical Oncology and Sir Y K Pao Cancer Center, Prince of Wales Hospital, Shatin, Hong Kong
    Cancer Chemother Pharmacol 62:59-64. 2008
    ..The epidermal growth factor receptor (EGFR) is commonly overexpressed in nasopharyngeal carcinoma (NPC) and gefitinib inhibits NPC growth in vitro...
  17. doi request reprint Management of hepatocellular carcinoma: beyond sorafenib
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Curr Oncol Rep 14:257-66. 2012
    ..This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed...
  18. ncbi request reprint Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer
    Calvin S H Ng
    Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shantin, NT, Hong Kong
    J Surg Oncol 79:101-6. 2002
    ..There have been few reports of its use in lung cancer. We investigate p16M in patients with non-small cell lung cancer (NSCLC)...
  19. doi request reprint Piloting electronic self report symptom assessment - Cancer (ESRA-C) in Hong Kong: a mixed method approach
    Carmen W H Chan
    The Nethersole School of Nursing, The Chinese University of Hong Kong, China
    Eur J Oncol Nurs 15:325-34. 2011
    ..This study aimed to assess the feasibility and acceptability of using an electronic self report symptom assessment tool among Chinese oncology patients...
  20. doi request reprint Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
    Masahiro Fukuoka
    Kinki University School of Medicine, Osaka, Japan
    J Clin Oncol 29:2866-74. 2011
    ..This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status...
  21. doi request reprint Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong State Key Laboratory in Oncology in South China
    J Clin Oncol 28:1660-5. 2010
    ..Hepatitis B virus (HBV) infection is an important etiology for hepatocellular carcinoma (HCC). We aim to develop a simple clinical score in predicting the risk of HCC among HBV carriers...